Circulating tumor DNA (ctDNA) are short DNA sequences shed by tumor cells into the systemic circulation. Studies have shown potential utility of the test to predict relapse or recurrence following treatment in solid tumors, but sensitivity and specificity have varied widely, ranging from 19-100% and 80-100% respectively, in breast cancer specifically. Moreover, literature describing the utility of monitoring dynamic changes in ctDNA trends is limited. We aim to evaluate the correlation between ctDNA test, both single test as well as dynamic trends in value over time, with imaging findings.
Karki,U, Ghimire B, Herrman E, Yadav S, Chisti M. Detection of progression or regression of breast cancer by circulating tumor DNA (ctDNA); 2022 Dec 6; San Antonio, TX.
Hematology Commons, Internal Medicine Commons, Oncology Commons
The San Antonio Breast Symposium Proceedings 2022 ; December 6 – 10, 2022; San Antonio, TX.